Since miR‐198/FOXP3 has a strong suppression on tumor cells, more powerful alternative inhibitors that direct at these two sites could be developed to better inhibit the proto‐oncogene MYC expression for clinical liver neoplasm treatment. This evidence concerns the gene FOXP3 and neoplasm.